Immatics (NASDAQ:IMTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. Chardan Capital’s price target would suggest a potential upside of 133.64% from the company’s current price.
Other analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Jefferies Financial Group initiated coverage on Immatics in a research report on Monday, March 16th. They issued a “buy” rating and a $18.00 target price on the stock. TD Cowen initiated coverage on Immatics in a research report on Tuesday, April 28th. They issued a “buy” rating on the stock. Finally, Mizuho set a $25.00 target price on Immatics in a research report on Thursday, February 19th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immatics currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.
Check Out Our Latest Stock Analysis on IMTX
Immatics Price Performance
Immatics (NASDAQ:IMTX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The company had revenue of $8.81 million during the quarter, compared to the consensus estimate of $9.79 million. Equities analysts forecast that Immatics will post -1.63 earnings per share for the current year.
Hedge Funds Weigh In On Immatics
Several hedge funds have recently modified their holdings of IMTX. Bank of America Corp DE boosted its stake in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares in the last quarter. Quarry LP acquired a new stake in shares of Immatics in the fourth quarter worth $84,000. Insigneo Advisory Services LLC acquired a new stake in shares of Immatics in the third quarter worth $103,000. Fox Run Management L.L.C. acquired a new stake in shares of Immatics in the fourth quarter worth $129,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of Immatics in the fourth quarter worth $206,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.
Immatics Company Profile
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
Read More
- Five stocks we like better than Immatics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
